Mirae Asset Global Etfs Holdings Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 53,163 shares of CRNX stock, worth $1.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
53,163
Previous 46,444
14.47%
Holding current value
$1.8 Million
Previous $2.37 Million
14.59%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$309 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$236 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$212 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$208 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$184 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.82B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...